Graypoint LLC’s Ginkgo Bioworks DNA Stock Holding History

Graypoint LLC’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-250	Closed	-$3.34K	–	494
2024 Q2	$3.34K	Sell	250 -7	-3%	-$209	﹤0.01%	473
2024 Q1	$11.9K	Buy	257 +7	+3%	+$362	﹤0.01%	454
2023 Q4	$16.9K	Buy	+250	New	+$15.3K	﹤0.01%	431

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Graypoint LLC's DNA Position: Q3 2024 in Review

Graypoint LLC sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 250 shares — an estimated $3.34K sold.

Graypoint LLC first reported a position in DNA in Q4 2023 and held it in 3 quarters. The position peaked at $16.9K in Q4 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

Graypoint LLC reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
Graypoint LLC sold 250 Ginkgo Bioworks shares in Q3 2024, an estimated $3.34K.
Graypoint LLC first reported a position in Ginkgo Bioworks in Q4 2023 and held it in 3 quarters.
Graypoint LLC's Ginkgo Bioworks position peaked at $16.9K in Q4 2023.
159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Graypoint LLC's 13F filing for Q3 2024, filed 31 Oct 2024.